BACKGROUND: Hermansky-Pudlak syndrome (HPS) is a common genetic disorder in Puerto Rico. In children with HPS, bleeding is the most disturbing and incapacitating problem. Desmopressin (1-deamino-8-D-arginine vasopressin, (DDAVP)) has been recommended in the management of bleeding disorders characterized by platelet dysfunction, such as HPS. METHODS: Nineteen pediatric Puerto Rican patients with HPS and prolonged bleeding time (BT) were tested for response to administration of DDAVP. RESULTS: Baseline BT was abnormal in 18 (95%) of the patients. The BT following DDAVP administration improved in two cases (11%): one from 7.2 to 5.6 min and the other from 8 to 6 min (Tables II and III). BT measurements remained very prolonged (>15 min) in 17 (89%) of the patients. Patients with the HPS 1 gene mutation had a statistically significant correlation with the poor response following DDAVP (P = 0.03). CONCLUSIONS: DDAVP seldom improves the BT of Puerto Rican children with HPS. Response to DDAVP should be determined individually and platelet transfusion should remain the treatment of choice for a major bleeding episode or surgical procedure. (c) 2004 Wiley-Liss, Inc.
BACKGROUND:Hermansky-Pudlak syndrome (HPS) is a common genetic disorder in Puerto Rico. In children with HPS, bleeding is the most disturbing and incapacitating problem. Desmopressin (1-deamino-8-D-arginine vasopressin, (DDAVP)) has been recommended in the management of bleeding disorders characterized by platelet dysfunction, such as HPS. METHODS: Nineteen pediatric Puerto Rican patients with HPS and prolonged bleeding time (BT) were tested for response to administration of DDAVP. RESULTS: Baseline BT was abnormal in 18 (95%) of the patients. The BT following DDAVP administration improved in two cases (11%): one from 7.2 to 5.6 min and the other from 8 to 6 min (Tables II and III). BT measurements remained very prolonged (>15 min) in 17 (89%) of the patients. Patients with the HPS 1 gene mutation had a statistically significant correlation with the poor response following DDAVP (P = 0.03). CONCLUSIONS: DDAVP seldom improves the BT of Puerto Rican children with HPS. Response to DDAVP should be determined individually and platelet transfusion should remain the treatment of choice for a major bleeding episode or surgical procedure. (c) 2004 Wiley-Liss, Inc.
Authors: Ellie Karampini; Maaike Schillemans; Menno Hofman; Floris van Alphen; Martin de Boer; Taco W Kuijpers; Maartje van den Biggelaar; Jan Voorberg; Ruben Bierings Journal: Haematologica Date: 2019-01-10 Impact factor: 9.941
Authors: Melissa A Merideth; Wendy J Introne; Jennifer A Wang; Kevin J O'Brien; Marjan Huizing; Bernadette R Gochuico Journal: Platelets Date: 2019-09-05 Impact factor: 3.862
Authors: Karla Claudio-Campos; Carmelo Orengo-Mercado; Jessicca Y Renta; Muriel Peguero; Ricardo García; Gabriel Hernández; Susan Corey; Carmen L Cadilla; Jorge Duconge Journal: Drug Metab Pers Ther Date: 2015-12
Authors: Souheil El-Chemaly; Kevin J O'Brien; Steven D Nathan; Gerald L Weinhouse; Hilary J Goldberg; Jean M Connors; Ye Cui; Todd L Astor; Philip C Camp; Ivan O Rosas; Merte Lemma; Vladislav Speransky; Melissa A Merideth; William A Gahl; Bernadette R Gochuico Journal: PLoS One Date: 2018-03-16 Impact factor: 3.240